Skip to main content

Lobbying activity

Who's lobbying Congress, for whom, and on what, from federal Lobbying Disclosure Act filings. Covers both chambers, synced daily. 278 filings

Top spenders & firms Spend by issue Political contributions Revolving door

  Showing filings that named HR 1492. Clear
Clear
Q2
GSK (FKA GLAXOSMITHKLINE INC.) for GSK (FKA GLAXOSMITHKLINE INC.)
2nd Quarter (Apr 1 - June 30) 2026 · District of Columbia · House · Senate
Budget/Appropriations, Copyright/Patent/Trademark, Health Issues, Medicare/Medicaid
View →
Q2
LUNDBECK LLC for LUNDBECK LLC
2nd Quarter (Apr 1 - June 30) 2026 · District of Columbia · House · Senate
Health Issues, Medicare/Medicaid, Trade (domestic/foreign)
View →
Q2
HEALTHCARE INSTITUTE OF NEW JERSEY for HEALTHCARE INSTITUTE OF NEW JERSEY
2nd Quarter (Apr 1 - June 30) 2026 · New Jersey · House · Senate
Health Issues
View →
Q2
E3 STRATEGIC CONSULTING GROUP for PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION
2nd Quarter (Apr 1 - June 30) 2026 · Virginia · House · Senate · $60,000.00 income
Pharmacy
View →
Q2
MARSHALL & POPP, LLC for SANOFI U.S. SERVICES, INC.
2nd Quarter (Apr 1 - June 30) 2026 · District of Columbia · House · Senate · $60,000.00 income
Pharmacy, Copyright/Patent/Trademark, Trade (domestic/foreign), Taxation/Internal Revenue Code
View →
Q2
MARSHALL & POPP, LLC for PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA
2nd Quarter (Apr 1 - June 30) 2026 · District of Columbia · House · Senate · $40,000.00 income
Pharmacy, Copyright/Patent/Trademark, Trade (domestic/foreign)
View →
Q2
MARSHALL & POPP, LLC for PFIZER, INC.
2nd Quarter (Apr 1 - June 30) 2026 · District of Columbia · House · Senate · $60,000.00 income
Pharmacy, Copyright/Patent/Trademark, Trade (domestic/foreign), Taxation/Internal Revenue Code
View →
Q2
MARSHALL & POPP, LLC for GENENTECH, INC.
2nd Quarter (Apr 1 - June 30) 2026 · District of Columbia · House · Senate · $60,000.00 income
Pharmacy, Copyright/Patent/Trademark, Trade (domestic/foreign)
View →
Q2
MARSHALL & POPP, LLC for AMGEN USA INC.
2nd Quarter (Apr 1 - June 30) 2026 · District of Columbia · House · Senate · $60,000.00 income
Pharmacy, Copyright/Patent/Trademark, Trade (domestic/foreign)
View →
Q2
LMH STRATEGIC SOLUTIONS for PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA
2nd Quarter (Apr 1 - June 30) 2026 · District of Columbia · House · Senate · $30,000.00 income
Pharmacy, Trade (domestic/foreign)
View →
Q2
AEGIS LLC for PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA
2nd Quarter (Apr 1 - June 30) 2026 · District of Columbia · House · Senate · $60,000.00 income
Pharmacy, Health Issues
View →
Q1
SOLENO THERAPEUTICS, INC. for SOLENO THERAPEUTICS, INC.
1st Quarter (Jan 1 - Mar 31) 2026 · California · House · Senate
Pharmacy, Trade (domestic/foreign), Financial Institutions/Investments/Securities, Health Issues
View →
RR
SOLENO THERAPEUTICS, INC. for SOLENO THERAPEUTICS, INC.
1st Quarter (Jan 1 - Mar 31) 2026 · California
Financial Institutions/Investments/Securities, Health Issues, Medicare/Medicaid, Insurance
View →
Q1
GSK (FKA GLAXOSMITHKLINE INC.) for GSK (FKA GLAXOSMITHKLINE INC.)
1st Quarter (Jan 1 - Mar 31) 2026 · District of Columbia · House · Senate
Budget/Appropriations, Copyright/Patent/Trademark, Health Issues, Medicare/Medicaid
View →
Q1
NEUROCRINE BIOSCIENCES, INC for NEUROCRINE BIOSCIENCES, INC
1st Quarter (Jan 1 - Mar 31) 2026 · California · House · Senate
Taxation/Internal Revenue Code, Medicare/Medicaid, Health Issues, Budget/Appropriations
View →
Q1
MONUMENT ADVOCACY for PHRMA
1st Quarter (Jan 1 - Mar 31) 2026 · House · Senate · $90,000.00 income
Trade (domestic/foreign), Foreign Relations, Health Issues
View →
Q1
EMD SERONO, INC. for EMD SERONO INC
1st Quarter (Jan 1 - Mar 31) 2026 · District of Columbia · House · Senate
Pharmacy, Veterans, Health Issues, Medicare/Medicaid
View →
Q1
BIOGEN for BIOGEN
1st Quarter (Jan 1 - Mar 31) 2026 · District of Columbia · House · Senate
Medicare/Medicaid, Health Issues, Pharmacy, Taxation/Internal Revenue Code
View →
Q1
AVENUE SOLUTIONS for GENENTECH USA, INC.
1st Quarter (Jan 1 - Mar 31) 2026 · California · House · Senate · $50,000.00 income
Medicare/Medicaid, Health Issues
View →
Q1
BAYER CORPORATION (CONSOLIDATED REPORT) for BAYER CORPORATION (CONSOLIDATED REPORT)
1st Quarter (Jan 1 - Mar 31) 2026 · District of Columbia · House · Senate
Copyright/Patent/Trademark, Tariff (miscellaneous tariff bills), Agriculture, Taxation/Internal Revenue Code
View →
Q1
THE MCMANUS GROUP for GILEAD SCIENCES, INC.
1st Quarter (Jan 1 - Mar 31) 2026 · California · House · Senate · $60,000.00 income
Medicare/Medicaid, Health Issues
View →
Q1
THE MCMANUS GROUP for GENENTECH
1st Quarter (Jan 1 - Mar 31) 2026 · District of Columbia · House · Senate · $50,000.00 income
Medicare/Medicaid, Health Issues, Taxation/Internal Revenue Code
View →
Q1
JOHNSON & JOHNSON SERVICES, INC. for JOHNSON & JOHNSON SERVICES INC
1st Quarter (Jan 1 - Mar 31) 2026 · New Jersey · House · Senate
Health Issues, Budget/Appropriations, Copyright/Patent/Trademark, Law Enforcement/Crime/Criminal Justice
View →
Q1
TODD STRATEGY GROUP for NOVARTIS, INC.
1st Quarter (Jan 1 - Mar 31) 2026 · District of Columbia · House · Senate · $60,000.00 income
Health Issues, Medicare/Medicaid, Trade (domestic/foreign)
View →
Q1
AMGEN, INC. for AMGEN INC
1st Quarter (Jan 1 - Mar 31) 2026 · District of Columbia · House · Senate
Health Issues, Medicare/Medicaid, Taxation/Internal Revenue Code, Copyright/Patent/Trademark
View →
Page 1 of 12 Next

Source: federal Lobbying Disclosure Act filings. A filing's bill references are parsed from its activity descriptions, so a bill page shows the filings that named it.

Report a problem